Provider: Alpha Street Research
Provider: Edison Investment Research
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Esperion Therapeutics Inc Announces Positive Top-Line Results From Phase 2 Clinical Study Of Oral Therapy In Patients With Hypercholesterolemia And History Of Statin Intolerance
Esperion Therapeutics Inc announced positive top-line results from a Phase 2a clinical study of lead product candidate ETC-1002 in patients with hypercholesterolemia with a history of intolerance to two or more statins. The study met primary endpoint, demonstrating that ETC-1002 lowered LDL-C by an average of 32% and was well tolerated. These data will be submitted for presentation at a future medical meeting and for publication in a peer-reviewed journal.
Latest Developments for Esperion Therapeutics Inc
Latest Key Developments in Biotechnology
- Jazz Pharmaceuticals PLC's Subsidiary and Gentium SpA announce agreement for Jazz Pharmaceuticals to acquire Gentium for $57.00 per share
- GeneNews Ltd announces conversion of convertible debentures into common shares
- Brainsway Ltd receives FDA approval of IDE for obsessive-compulsive disorder study
- IntegraGen SA sequences more than 100 breast cancer metastases
- Share this
- Digg this